Anil Yaman

  • Citations Per Year
Learn More
ClinicalTrials.gov has been archiving clinical trials since 1999, with > 165,000 trials at present. It is a valuable but relatively untapped resource for understanding trial design patterns and acquiring reusable trial design knowledge. We extracted common eligibility features using an unsupervised tag-mining method and mined their temporal usage patterns(More)
This paper presents a method for classifying and structuring free-text clinical trial eligibility criteria using the OMOP Common Data Model (CDM). Our method was applied to eligibility criteria text available from the largest clinical trial repository ClinicalTrials.gov. Structurally complex criteria were simplified and rewritten as simpler sentences(More)
Objective The population representativeness of a clinical study is influenced by how real-world patients qualify for the study. We analyze the representativeness of eligible patients for multiple type 2 diabetes trials and the relationship between representativeness and other trial characteristics. Methods Sixty-nine study traits available in the(More)
The autonomously trading agents described in this paper produce a decision to act such as: buy, sell or hold, based on the input data. In this work, we have simulated autonomously trading agents using the Echo State Network (ESNs) model. We generate a collection of trading agents that use different trading strategies using Evolutionary Programming (EP). The(More)
Terminologies can suffer from poor concept coverage due to delays in addition of new concepts. This study tests a similarity-based approach to recommending concepts from a text corpus to a terminology. Our approach involves extraction of candidate concepts from a given text corpus, which are represented using a set of features. The model learns the(More)
Knowledge reuse of cancer trial designs may benefit from a temporal understanding of the evolution of the target populations of cancer studies over time. Therefore, we conducted a retrospective analysis of the trends of cancer trial eligibility criteria between 1999 and 2014. The yearly distributions of eligibility concepts for chemicals and drugs,(More)
  • 1